title: Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.
abstract: OBJECTIVE
  To investigate a possible association between gene variants and patient response to treatment with intravitreal ranibizumab for neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Visual acuity score (VAS) was recorded at baseline and a subsequent visit at 6 months. Genotypes of 3 polymorphisms in known AMD susceptibility loci (rs1061170 in complement factor H (CFH), rs11200638 in HTRA1 and rs1413711 in VEGF) were determined. Central retinal thickness and maximum thickness of the lesion were also measured.
  
  
  RESULTS
  A total of 168 neovascular AMD patients treated with intravitreal ranibizumab were included in our study. For HTRA1 rs11200638, mean VAS changes were 3.5, 9.4 and 10.6 letters for the AA, AG and GG genotypes, respectively (p = 0.022). In contrast, for CFH rs1061170 and VEGF rs1413711, mean VAS changes were not significant. However, there was no significant difference in the changes in central retinal thickness and maximum lesion thickness among the genotypes of the tested single-nucleotide polymorphisms.
  
  
  CONCLUSIONS
  HTRA1 gene polymorphism may influence patient response to treatment with intravitreal ranibizumab for neovascular AMD.
authors.affiliation: Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
authors.forename: Dongqing
authors.initials: D
authors.lastname: Yuan
authors.forename: Donglan
authors.initials: D
authors.lastname: Yuan
authors.forename: Xiaoyi
authors.initials: X
authors.lastname: Liu
authors.forename: Songtao
authors.initials: S
authors.lastname: Yuan
authors.forename: Ping
authors.initials: P
authors.lastname: Xie
authors.forename: Qinghuai
authors.initials: Q
authors.lastname: Liu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D002681:China; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D005838:Genotype; D000074289:High-Temperature Requirement A Serine Peptidase 1; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D000069579:Ranibizumab; D012697:Serine Endopeptidases / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000235:genetics
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C493495:CFH protein, human; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D017242:Complement Factor H; D000074289:High-Temperature Requirement A Serine Peptidase 1; C474012:HTRA1 protein, human; D012697:Serine Endopeptidases; D000069579:Ranibizumab